Century Therapeutics, Inc. (IPSC): restructuring charge — Century Therapeutics cuts 51% of workforce; CFO and CDO to depart

Century Therapeutics, Inc.

Board approved reduction in force of ~51% of employees; expects $3.7M in severance costs.
CFO Morgan Conn to depart effective July 11; SVP Finance Douglas Carr named interim principal financial officer.
Chief Development Officer Adrienne Farid to depart effective July 31.
Workforce reduction substantially complete by end of Q3 2025; company focusing on highest-potential programs.

item 2.05 item 5.02

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Century Therapeutics, Inc. announced a restructuring with charges of approximately $3.7 million (approximately 51%).

Type: restructuring
Charge: approximately $3.7 million
Headcount: approximately 51%

Exact text from the filing

On July 1, 2025, the Board of Directors (the “ Board ”) of Century Therapeutics, Inc. (the “ Company ”) approved a reduction in force as part of a broader effort to right size the organization to focus on programs with the highest potential for transformational value. The Company expects to implement a net reduction of its employee headcount by approximately 51% (the “ RIF ”). As part of the RIF, the Company estimates that it will incur charges of approximately $3.7 million for severance and other employee termination-related costs.

View on SEC.gov

6 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

Century Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-066091

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.